When: Confirmed close above 10 EMA at $261.29 with volume expansion >8M shares

Then: 10-15% of intended sizing tactical add

HOLD; maintain existing position size; preserve $235 stop-loss (below 200 SMA at $240.20); defer to defined entry triggers at $240 flush or $265 breakout

• RSI at 29.57 oversold is descriptive of past price action, not predictive of reversal—MACD histogram at negative 2.13 is still expanding, indicating accelerating downside momentum
• Forward P/E of 21x on current price ~254-255 versus historical 15-18x range represents 17-40% premium regardless of EPS normalization adjustments
• PEG ratio of 2.65 on 6% revenue growth is rich; headline EPS growth looks weak and the denominator is what it is
• Stelara biosimilar erosion bulk impact is still ahead in 2026-2027, not behind; compounding at mid-single-digit revenue growth while facing peak generic competition is running hard to stay in place
• Dividend yield of 2.12% with nearly 200bps yield gap to risk-free assets causes income-oriented buyers to step aside, triggering multiple compression
• JNJ down 9% from 52-week high, trading below 50-day moving average and 10 EMA at lower Bollinger Band—defensive rotation thesis is not working because firm-specific risks (talc, Stelara cliff, $17.5B M&A, net debt doubling to $28.6B) overwhelm macro tailwind
• Polymarket 86% beat probability is already priced into the stock; asymmetric downside (miss, cautious guide, talc reserve top-up) is more impactful than upside surprise at current price
• $17.5B in 2025 acquisitions doubled net debt from $12.5B to $28.6B; goodwill and intangibles at 48% of total assets; tangible book value negative—mature company levering up to defend growth
• Talc litigation is 'recurring source of non-operating volatility' per fundamentals report; material adverse outcome could trigger 5-10% single-session drawdown on October 13 Q3 print
• Sentiment data is 'neutral, low confidence, no signal'—absence of bearish sentiment is not bullish evidence

→ vs aggressive: RSI at 29.57 and Bollinger Band tag do not constitute 'selling exhaustion'—MACD histogram at negative 2.13 is deepening, 50 SMA has rolled over bearish, and bounce came on declining volume flagged as 'yellow flag' by technical report itself

→ vs aggressive: Forward P/E of 21x represents 17-40% premium to historical 15-18x range even accepting all normalization adjustments; re-rating based on depressed EPS normalizing is temporary optical illusion, not permanent re-rating

→ vs aggressive: PEG of 2.65 on 6% revenue growth is rich regardless of talc noise adjustments; high single to low double digit EPS growth profile is optimistic

→ vs aggressive: Stelara biosimilar erosion bulk impact is still ahead in 2026-2027; compounding at mid-single digits through peak generic competition year is running to stay in place, not absorbing the headwind

→ vs aggressive: Dividend yield gap of nearly 200bps causes income-oriented buyer base (retirees, income institutions) to step aside, triggering multiple compression—visible in current price action below all short-term moving averages

→ vs aggressive: Firm-specific risks (talc litigation, Stelara cliff, $17.5B M&A integration, net debt doubling) overwhelm defensive rotation macro tailwind; if rotation thesis were working, stock would not be down 9% from 52-week high

→ vs aggressive: 86% Polymarket beat probability is already priced in; asymmetric upside requires blowout beat plus constructive 2027 guidance; asymmetric risk is actually to the downside given firm-specific risks

→ vs aggressive: Proposed $245 stop-loss is essentially at 200 SMA ($240.20) and will get stopped out on routine whipsaw; existing $235 stop provides proper buffer below major support

→ vs aggressive: Adding on capitulation to a broken thesis is not stop-loss discipline—it is averaging into a broken thesis which compounds concentrated losses

→ vs aggressive: Net debt doubling from $12.5B to $28.6B in one year, goodwill/intangibles at 48% of assets, and negative tangible book value represent leverage risk in higher-rate environment, not picture of unassailable defensive compounder

→ vs aggressive: Talc litigation is 'recurring source of non-operating volatility' per fundamentals report, not 'largely resolved'; 5-10% single-session drawdown risk on October 13 not priced into Polymarket

→ vs aggressive: Sentiment data 'neutral, low confidence, no signal' is absence of evidence, not bullish evidence; treating absence of bearish signal as bullish is unsupported by data

HOLD core position; small tactical add on confirmation only (10-15% of intended sizing, conditional on daily close above 10 EMA at 261.29 with volume above 8 million shares); keep 235 stop; use Q3 print as reassessment trigger; consider collar/covered call into print; consider diversifying defensive exposure via basket approach

• 200 SMA support at 240 is rising, validating structural uptrend
• RSI touched 29.57 at lower Bollinger Band with contracting ATR (4.99) is classic exhaustion signature
• Forward EPS of 12.10 on clean earnings; 21x multiple reasonable for 25.7% ROE
• $22 billion annualized free cash flow; beta 0.21; $17.5 billion M&A with net debt doubling
• Polymarket beat probability at 86% is already priced; binary event risk with asymmetric downside (5-8% gap possible on cautious guide or talc reserve top-up)
• Sentiment data neutral with no crowding; absence of forced selling is constructive
• 235 stop properly placed for binary event window; 245 stop will get whipsawed or gapped through
• Conservative and aggressive cases both legitimate; right response is preserving optionality
• Consider collar or covered call into print to monetize elevated implied vol
• Defensive rotation tailwind may be better expressed via basket than firm-specific JNJ exposure

→ vs aggressive: Binary catalyst timing is wrong—86% Polymarket probability is already priced; 245 stop will be gapped through or whipsawed on noise; 25-50% sizing adds unnecessary event risk; valuation re-rating requires EPS beat plus raised guidance or sector rotation, not guaranteed; treating JNJ as defensive sector ETF ignores firm-specific overhang from Stelara erosion, talc litigation, and M&A debt

→ vs conservative: Technical setup is not uniformly bearish—oversold RSI at 29.57 with ATR contraction creates better risk-reward than at higher levels; macro rotation thesis is structural, not just timing—lag underperformance signals relative-value opportunity, not thesis failure; absence of crowding is feature not bug—no forced selling or overhang; strategic franchise quality (25.7% ROE, $22B FCF, 60-year dividend aristocrat) must inform tactical decisions